Environmental Toxins and Alzheimer’s Disease: a Comprehensive Analysis of Pathogenic Mechanisms and Therapeutic Modulation

被引:0
|
作者
Rishika Dhapola
Prajjwal Sharma
Sneha Kumari
Jasvinder Singh Bhatti
Dibbanti HariKrishnaReddy
机构
[1] Central University of Punjab,Advanced Pharmacology and Neuroscience Laboratory, Department of Pharmacology
[2] Central University of Punjab,Laboratory of Translational Medicine and Nanotherapeutics, Department of Human Genetics and Molecular Medicine
来源
Molecular Neurobiology | 2024年 / 61卷
关键词
Alzheimer’s disease; Environmental pollutants; Heavy metals; PARP; SIRT1; MAPK/ERK;
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer’s disease is a leading cause of mortality worldwide. Inorganic and organic hazards, susceptibility to harmful metals, pesticides, agrochemicals, and air pollution are major environmental concerns. As merely 5% of AD cases are directly inherited indicating that these environmental factors play a major role in disease development. Long-term exposure to environmental toxins is believed to progress neuropathology, which leads to the development of AD. Numerous in-vitro and in-vivo studies have suggested the harmful impact of environmental toxins at cellular and molecular level. Common mechanisms involved in the toxicity of these environmental pollutants include oxidative stress, neuroinflammation, mitochondrial dysfunction, abnormal tau, and APP processing. Increased expression of GSK-3β, BACE-1, TNF-α, and pro-apoptotic molecules like caspases is observed upon exposure to these environmental toxins. In addition, the expression of neurotrophins like BDNF and GAP-43 have been found to be reduced as a result of toxicity. Further, modulation of signaling pathways involving PARP-1, PGC-1α, and MAPK/ERK induced by toxins have been reported to contribute in AD pathogenesis. These pathways are a promising target for developing novel AD therapeutics. Drugs like epigallocatechin-gallate, neflamapimod, salsalate, dexmedetomidine, and atabecestat are in different phases of clinical trials targeting the pathways for possible treatment of AD. This review aims to culminate the correlation between environmental toxicants and AD development. We emphasized upon the signaling pathways involved in the progression of the disease and the therapeutics under clinical trial targeting the altered pathways for possible treatment of AD.
引用
收藏
页码:3657 / 3677
页数:20
相关论文
共 50 条
  • [21] Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies
    Gao, Yu
    Tan, Lin
    Yu, Jin-Tai
    Tan, Lan
    CURRENT ALZHEIMER RESEARCH, 2018, 15 (03) : 283 - 300
  • [22] The Therapeutic Potential of Melatonin in Alzheimer's Disease: A Comprehensive Review
    Zhang, Jialang
    Feng, Mingzhe
    Kong, Lingbo
    CURRENT MEDICINAL CHEMISTRY, 2024,
  • [23] Dysfunctional autophagy in Alzheimer's disease: pathogenic roles and therapeutic implications
    Liang, Jun-Hua
    Jia, Jian-Ping
    NEUROSCIENCE BULLETIN, 2014, 30 (02) : 308 - 316
  • [24] Dysfunctional autophagy in Alzheimer's disease: pathogenic roles and therapeutic implications
    Jun-Hua Liang
    Jian-Ping Jia
    Neuroscience Bulletin, 2014, 30 (02) : 308 - 316
  • [25] Dysfunctional autophagy in Alzheimer’s disease: pathogenic roles and therapeutic implications
    Jun-Hua Liang
    Jian-Ping Jia
    Neuroscience Bulletin, 2014, 30 : 308 - 316
  • [26] Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications
    Wang, Jun
    Bi, Weina
    Cheng, Alice
    Freire, Daniel
    Vempati, Prashant
    Zhao, Wei
    Gong, Bing
    Janle, Elsa M.
    Chen, Tzu-Ying
    Ferruzzi, Mario G.
    Schmeidler, James
    Ho, Lap
    Pasinetti, Giulio M.
    FRONTIERS IN AGING NEUROSCIENCE, 2014, 6
  • [27] Tetrahydrobiopterin Availability in Parkinson’s and Alzheimer’s Disease; Potential Pathogenic Mechanisms
    Richard H. Foxton
    John M. Land
    Simon J. R. Heales
    Neurochemical Research, 2007, 32 : 751 - 756
  • [28] Tetrahydrobiopterin availability in Parkinson's and Alzheimer's disease; Potential pathogenic mechanisms
    Foxton, Richard H.
    Land, John M.
    Heales, Simon J. R.
    NEUROCHEMICAL RESEARCH, 2007, 32 (4-5) : 751 - 756
  • [29] Microbiota modulation as preventative and therapeutic approach in Alzheimer's disease
    Bonfili, Laura
    Cecarini, Valentina
    Gogoi, Olee
    Gong, Chunmei
    Cuccioloni, Massimiliano
    Angeletti, Mauro
    Rossi, Giacomo
    Eleuteri, Anna Maria
    FEBS JOURNAL, 2021, 288 (09) : 2836 - 2855
  • [30] Pyramidal neurone modulation: A therapeutic target for Alzheimer's disease
    Francis, PT
    NEURODEGENERATION, 1996, 5 (04): : 461 - 465